Larotrectinib (Vitaika) resistance symptoms and early detection and treatment methods

Larotrectinib is a highly selective TRK inhibitor targeting NTRK gene fusion-positive tumors and has shown significant efficacy in the treatment of a variety of adult and pediatric tumors. However, as with most targeted drugs, patients may develop resistance during long-term use. Common resistance mechanisms include secondary mutations in the NTRK gene, activation of downstream signaling pathways, and the emergence of alternative signaling pathways. These mechanisms will lead to the weakening of the inhibitory effect of drugs on tumor cells, leading to disease progression or recurrence.

Clinically, early symptoms of larotrectinib resistance often manifest as a re-exacerbation of tumor-related symptoms. For example, symptoms such as pain, cough, dyspnea, or gastrointestinal discomfort that were originally well-controlled reappear, or imaging examinations reveal an increase in tumor size and an increase in metastases. Some patients may also experience abnormalities in blood indicators, such as increased levels of tumor markers. Therefore, resistance usually does not occur suddenly but is manifested through clinical signs that gradually appear.

In order to detect resistance early, patients need to undergo regular imaging examinations (such as CT, MRI or PET-CT) and laboratory tests during larotrectinib treatment. At the same time, the attending physician usually recommends regular assessment of tumor marker levels and a comprehensive judgment based on the patient's clinical manifestations. If it is found that the disease relapses or the efficacy decreases within a short period of time, the possibility of drug resistance should be suspected, and genetic testing should be performed promptly to determine whether there are new mutations or activation of alternative signaling pathways.

Once resistance is confirmed, treatment methods need to be individualized. For patients with local drug resistance, local treatments, such as surgical resection or radiotherapy, may be considered; for patients with systemic drug resistance, second-generation TRK inhibitors (such as selitrectinib or repotrectinib) may need to be replaced to overcome resistance caused by mutations. At the same time, some patients may also benefit from combination treatment options, such as combination chemotherapy, immunotherapy or other targeted drugs. During this process, patients need to communicate closely with their doctors and adjust the treatment plan according to their own condition, so as to delay the progression of the disease as much as possible and improve the quality of life.

Reference materials:https://www.drugs.com/